Cargando…

588. Ceftolozane/Tazobactam Susceptibility of Carbapenem-Resistant Pseudomonas aeruginosa and Carbapenem-Resistant Enterobacterales Isolates in a Tertiary Hospital in Korea

BACKGROUND: Carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) are significant nosocomial pathogens that pose significant challenges in treatment due to their multidrug-resistant nature. Ceftolozane/tazobactam (C/T) is a novel antimicrobial agent that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Kye-Hyung, Moon, Seulgi, Ko, Mee Kyung, Yi, Jongyoun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679311/ http://dx.doi.org/10.1093/ofid/ofad500.657

Ejemplares similares

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
por: Teo, Jocelyn Qi-Min, et al.
Publicado: (2021)

Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa
por: Gill, Christian M, et al.
Publicado: (2022)

Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant Pseudomonas aeruginosa
por: Nasomsong, Worapong, et al.
Publicado: (2022)

Identification and infection control of carbapenem-resistant Enterobacterales in intensive care units
por: Yi, Jongyoun, et al.
Publicado: (2021)

1219. Unfavorable Clinical Outcomes with Polymyxins Compared to Ceftolozane/Tazobactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa
por: Howard-Anderson, Jessica, et al.
Publicado: (2021)

Satisfactory In Vitro Activity of Ceftolozane–Tazobactam against Carbapenem-Resistant Pseudomonas aeruginosa But Not against Klebsiella pneumoniae Isolates
por: Sękowska, Alicja, et al.
Publicado: (2023)

2423. Effectiveness and Safety of Ceftolozane/Tazobactam (TOL/TAZ) Use for Carbapenem-Resistant Pseudomonas Infections in Children
por: Molloy, Leah, et al.
Publicado: (2018)

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
por: Barnes, Melissa D., et al.
Publicado: (2018)

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020)

The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa
por: Gill, Christian M., et al.
Publicado: (2021)

Ceftolozane-tazobactam for the Treatment of Multi Drug-resistant Pseudomonas aeruginosa (MDRPA) Infections
por: Molnar, Esther, et al.
Publicado: (2017)

Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
por: Contreras-Gómez, María José, et al.
Publicado: (2022)

Ceftolozane-Tazobactam Resistance in Multidrug-Resistant Pseudomonas aeruginosa Isolates Not Associated with AmpC Activity
por: Tran, Truc T, et al.
Publicado: (2017)

Ceftolozane/Tazobactam-Induced Leukocytosis and Clinical Failure in a Patient Being Treated for Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Pseudomonas aeruginosa: a Case Report
por: Maniara, Bejoy P., et al.
Publicado: (2021)

415 In Vitro Potency of Ceftolozane/Tazobactam against Pseudomonas aeruginosa Displaying Multidrug Resistance
por: Sutherland, Christina, et al.
Publicado: (2014)

292. Ceftolozane/Tazobactam for Treatment of Osteomyelitis due to Multi-Drug-Resistant Pseudomonas aeruginosa
por: Gerlach, Anthony, et al.
Publicado: (2018)

Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study
por: Gallagher, Jason C, et al.
Publicado: (2018)

2291. Evaluation of Multidrug-Resistant Pseudomonas aeruginosa Isolates in Patients Receiving Ceftolozane/tazobactam
por: Bodo, Emily C, et al.
Publicado: (2019)

349. Hardware-Associated Multidrug-resistant Pseudomonas aeruginosa Meningitis Treated with Ceftolozane-Tazobactam
por: Li, Caitlin, et al.
Publicado: (2020)

Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients
por: Coppola, Paolo E., et al.
Publicado: (2020)

Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance
por: Simner, Patricia J, et al.
Publicado: (2021)

Carbapenem-resistant Pseudomonas aeruginosa and carbapenem use in Japan: an ecological study
por: Terahara, Fumitaka, et al.
Publicado: (2019)

Prevalence and Risk Factors of Carbapenem-resistant Enterobacteriaceae Acquisition in an Emergency Intensive Care Unit in a Tertiary Hospital in Korea: a Case-Control Study
por: Kang, Jin Suk, et al.
Publicado: (2019)

Correlation Between Virulence Genotype and Fluoroquinolone Resistance in Carbapenem-Resistant Pseudomonas aeruginosa
por: Cho, Hye Hyun, et al.
Publicado: (2014)

Ceftolozane/Tazobactam Dosing Requirements Against Pseudomonas aeruginosa Bacteremia
por: Ruiz, Jesus, et al.
Publicado: (2020)

Resistance of Animal Strains of Pseudomonas aeruginosa to Carbapenems
por: Haenni, Marisa, et al.
Publicado: (2017)

Susceptibility of Meropenem-Resistant and/or Carbapenemase-Producing Clinical Isolates of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa to Ceftazidime-Avibactam and Ceftolozane-Tazobactam as Assessed by In Vitro Testing Methods
por: Cortazzo, Venere, et al.
Publicado: (2022)

Postoperative soft-tissue infection due to multidrug-resistant Pseudomonas aeruginosa: usefulness of ceftolozane-tazobactam
por: Monterrubio-Villar, Jesús, et al.
Publicado: (2018)

Stewardship Nightmare: Ceftolozane/Tazobactam–Resistant Pseudomonas aeruginosa Infections Accelerated by the COVID-19 Pandemic
por: Haviland, Adam, et al.
Publicado: (2021)

Experience With Ceftolozane-Tazobactam for the Treatment of Serious Pseudomonas aeruginosa Infections in Saudi Tertiary Care Center
por: Bosaeed, M, et al.
Publicado: (2020)

Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries
por: García-Betancur, Juan Carlos, et al.
Publicado: (2022)

Ceftolozane/tazobactam heteroresistance in cystic fibrosis-related Pseudomonas aeruginosa infections
por: Monogue, Marguerite L, et al.
Publicado: (2023)

Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018)
por: Cantón, Rafael, et al.
Publicado: (2021)

1450. Frequency of Carbapenem-resistant Pseudomonas aeruginosa Among Respiratory Pathogens Impacts First-Line Beta-Lactam Susceptibility: Potential Role for Ceftolozane/Tazobactam (C/T) and/or Imipenem/Relebactam (I/R)
por: Klinker, Kenneth, et al.
Publicado: (2020)

Persistent Bacteremia from Pseudomonas aeruginosa with In Vitro Resistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-Avibactam
por: Gangcuangco, Louie Mar, et al.
Publicado: (2016)

Activity of mecillinam against carbapenem-resistant Enterobacterales
por: Emeraud, Cécile, et al.
Publicado: (2022)

Updates on the Status of Carbapenem-Resistant Enterobacterales in Lebanon
por: Fadlallah, Mahdi, et al.
Publicado: (2023)

Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 study
por: Belkhair, J., et al.
Publicado: (2021)

Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa
por: Papadomanolaki, Arhodoula, et al.
Publicado: (2022)

2150. In Vitro Activity of Cefepime-Taniborbactam and Comparators Against Genotypically Characterized Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Pseudomonas aeruginosa (CRPA) from the United States, 2018-2021
por: Wise, Mark G, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6a183t7iakqmi3tntrsmkorjko